Skip to main content

Out-of-Pocket Costs Considerable, Increasing for Prostate Cancer Diagnostic Testing

Medically reviewed by Carmen Pope, BPharm. Last updated on July 15, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 15, 2024 -- For patients with private insurance undergoing diagnostic testing after prostate-specific antigen (PSA)-based screening, out-of-pocket costs are considerable and increased from 2010 to 2020, according to a study published online July 15 in Cancer.

Arnav Srivastava, M.D., M.P.H., from the University of Michigan in Ann Arbor, and colleagues identified men aged 55 to 69 years who underwent PSA-based prostate cancer screening from 2010 to 2020. The number of men undergoing follow-up diagnostic testing within 12 months of screening was examined, and men were categorized as biopsy only, magnetic resonance imaging (MRI) only, and MRI + biopsy.

Of the 3,075,841 screened men from 2010 through 2020, 91,850 had a second PSA test and elevated PSA level; of these, 43.9 percent underwent subsequent diagnostic testing. The researchers found that >75 percent of these patients experienced cost-sharing. During the study period, there was a considerable increase in median out-of-pocket costs for patients undergoing biopsy only ($79 to $214), MRI only ($81 to $490), and MRI + biopsy ($353 to $620).

"For some patients, these costs may be significant and stand to deter necessary care following prostate cancer screening," the authors write. "Consequently, we recommend that policymakers and payers consider prostate cancer screening a multistep process and eliminate cost-sharing for indicated diagnostic testing."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2024

Read this next

2020 to 2023 Saw Increase in Buprenorphine Dispensing for Teens

THURSDAY, Dec. 26, 2024 -- Buprenorphine dispensing increased among adolescents and decreased among young adults between 2020 and 2023, according to a research letter published...

Prevalence of Post-COVID-19 Condition in Adults 8.4 Percent in 2023

THURSDAY, Dec. 26, 2024 -- The prevalence of post-COVID-19 condition (PCC) was 8.4 percent among U.S. adults in 2023, according to a research letter published online Dec. 13 in...

COVID-19 Infection Not Linked to Changes in MS Symptom Severity

THURSDAY, Dec. 26, 2024 -- COVID-19 infection is not associated with immediate changes in multiple sclerosis (MS) symptom severity or disability, according to a study published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.